Drugs / PBF-509
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02111330 | Mar → May 2014 | Parkinson disease | Sant Pau Research Institute | Completed | No outcome recorded |
| Phase 1 | NCT01691924 | Oct 2012 → Oct 2013 | Parkinson disease | Sant Pau Research Institute | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PBF-509 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01691924 ↗ |
| Route | Oral | “single oral, dose-escalating, and placebo-controlled design” NCT01691924 ↗ |